Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15018117 | 0.80 | GAA (0.42) | TSHRLMNAPOLBL3MBTL1 | |
| SCHEMBL3209417 | 0.80 | GAA (0.46) | TSHRPOLBL3MBTL1 | |
| SCHEMBL6649340 | 0.79 | KMT2A (0.56) | TSHRSMN1; SMN2LMNAPOLB | |
| SCHEMBL3204515 | 0.78 | GAA (0.49) | TSHRPOLBL3MBTL1 | |
| SCHEMBL27021615 | 0.77 | MEN1 (0.45) | CA12CA7CA14TSHRSMN1; SMN2 | |
| SCHEMBL5119622 | 0.76 | POLB (0.47) | TSHRSMN1; SMN2LMNAPOLBL3MBTL1 | |
| SCHEMBL25229177 | 0.75 | KDM4E (0.42) | CA12TSHRPOLBHSD17B10 | |
| SCHEMBL3207323 | 0.75 | SMN1; SMN2 (0.40) | SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL23141239 | 0.73 | APEX1 (0.43) | LMNA | |
| Hydrochloric Acid SCHEMBL7085128 | 0.73 | POLB (0.39) | CA12TSHRSMN1; SMN2LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0592439-B1 | AMINOSULFONYL CARBAMATES | WARNER LAMBERT CO (US) | 2003-07-30 | — | — | EP | claimed |
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
| EP-0592439-A1 | AMINOSULFONYL CARBAMATES | WARNER-LAMBERT COMPANY (US) | 1994-04-20 | — | — | EP | disclosed |
| WO-1992008693-A1 | AMINOSULFONYL CARBAMATES | WARNER-LAMBERT COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | CA12 1162/4885CA7 166/4885CA14 913/4885 |
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | CA12 3251/4885CA7 1418/4885CA14 2880/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | CA12 3135/4885CA7 1554/4885CA14 3444/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | CA12 3251/4885CA7 1418/4885CA14 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.